Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that topical diphenylcyclopropenone was effective in treating severe alopecia areata but had a high relapse rate and was often accompanied by side effects like eczema and lymphadenopathy.

This study found that retinol palmitate treatment in patients with stage Ia non-small-cell lung cancer may reduce cancer relapses, but longer follow-up is needed to confirm its efficacy.

This study reported two cases of alopecia areata where hair regrowth was achieved with zinc gluconate and sulfur amino acids after relapse post-PUVA cessation, suggesting potential zinc responsiveness in some patients.

This report describes onset, regrowth, and relapse patterns in alopecia areata and proposes mechanisms to integrate into current theories, with no new clinical results.

Intradermal PRP significantly improved melasma in dark skin, with lasting results and no relapse after 3 months.

This case report describes a 40-year-old man whose vitiligo and psoriasis responded favorably to ixekizumab after experiencing vitiligo onset and psoriasis relapse during adalimumab treatment.

In this study, a group taking compound ginseng cicada decoction showed significantly lower relapse rates, severity, and itching related to atopic dermatitis over 3 months compared to a control group, and reported improved quality of life with no significant adverse events.

This study found that pediatric patients with severe alopecia areata showed significant improvement with systemic corticosteroids but typically experienced relapse within 4-5 months, also seeing an increase in weight percentiles.

This review discusses the complex etiology and pathogenesis of vitiligo, noting challenges in treatment effectiveness and relapse, and reports no new clinical results.

The researchers reported that treating Alopecia Areata patients with the homeopathic remedy Fluoric Acid resulted in substantial hair regrowth and reduced relapse rates over a 6-year period, suggesting it may be an effective alternative to conventional treatments.

This case study reports that a man with severe patch-type alopecia areata initially responded to baricitinib treatment but experienced a relapse despite ongoing therapy.

In this study, increased treatment duration with vismodegib was associated with a decreased risk of relapse in patients with advanced or multiple basal cell carcinoma.

Treatments for acute leukaemia lead to high remission rates, but relapses occur, requiring ongoing advancements in care.

Alopecia areata's causes are unclear, treatments exist but relapses are common.

This study reviewed recent theories on alopecia areata's pathogenesis, highlighting its autoimmune nature due to immune privilege disruption in hair follicles, and noted current treatments have limited efficacy with high relapse rates, underscoring the need for further research into its mechanisms for better therapies.

This review discusses immune privilege in anagen hair follicles and its collapse in alopecia areata, emphasizing the importance of restoring this function for effective management and disease relapse prevention.

This study found that group behavior therapy for trichotillomania led to greater short-term symptom improvement compared to supportive therapy, but did not achieve clinically significant changes or prevent relapse over six months.

This study found that oral JAK inhibitors, ruxolitinib and tofacitinib, are effective and well-tolerated for treating severe alopecia areata, with a similar degree of hair regrowth and relapse rates, but ruxolitinib induced faster initial hair regrowth.

This study found that all lesions in mice treated with a new topical formulation, WR 279,396, healed completely without relapse, outperforming other formulations and showing no toxicity.

This study observed that topical PUVA treatment led to excellent or good hair regrowth in 45.4% of patients with alopecia areata, though many experienced relapse after treatment stopped.

This systematic review of pulse corticosteroid therapy for alopecia areata found relatively low complete response rates, but responders experienced low relapse rates, indicating potential benefits for patients with favorable prognostic factors.

This case series found that oral tofacitinib treatment in eight adolescents with alopecia universalis led to significant regrowth of hair, though relapse is likely after stopping therapy.

This review discusses the variability and limitations of treatments for severe alopecia areata, noting some patients may achieve cosmetic hair regrowth with treatment, while others experience persistent hair loss or relapse.

In this study, the researchers found that treatment with the JAK inhibitor tofacitinib in alopecia areata patients may reduce clonal CD8+ T cell expansions but does not eliminate them entirely, which could contribute to disease relapse.

This study found that most patients with folliculitis decalvans showed improvement and remission with oral antibiotics, although some experienced relapses and required prolonged treatment.

This study found that diphenylcyclopropenone therapy resulted in over 50% hair regrowth in 71% of alopecia totalis patients, with a significant relapse association with thyroid disease, suggesting treatment could be viable but should continue for at least two years.

This study found that intravenous high-dose pulse corticosteroids resulted in a complete response in 38% of children with alopecia areata, but the majority of responders relapsed within a year.

This report examines efforts to enhance the efficacy of topical steroids for alopecia areata using penetration-enhancing vehicles and exceptionally high concentrations, noting systemic steroids often lead to relapses and toxicity.

This study observed that methotrexate combined with low- to moderate-dose oral corticosteroids may effectively treat severe alopecia areata, though long-term maintenance is often necessary due to relapse after tapering.

This review analyzed data on alopecia types associated with COVID-19, suggesting androgenetic alopecia may be a risk factor for severe COVID-19, while telogen effluvium often follows infection and alopecia areata tends to relapse in those with preexisting disease.